Chimeric antigen receptors: unleashing a new age of anti-cancer therapy
Open Access
- 14 November 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Cell International
- Vol. 18 (1), 1-6
- https://doi.org/10.1186/s12935-018-0685-x
Abstract
Chimeric antigen receptors (CARs) represent a novel facet of modern day synthetic biology that exemplifies personalized medicine at work through their ability to harness and redirect a patient’s immune system to fight cancer. By combining the target-specificity of antibodies to the effector capabilities of T cells, CARs have yielded high remission rates for many late staged and relapsed/refractory (r/r) hematological malignancies, including acute lymphoblastic leukemias (ALL) and Non-Hodgkin’s lymphomas. Despite toxicities of cytokine release syndrome and neurotoxicity, recent studies have uncovered their underlying mechanisms and devised effective therapies to manage and possibly prevent them. In 2017, CAR T cell therapy became a reality for the general public despite the high costs, when Novartis’s Kymriah, became the first product to receive FDA approval for pediatric r/r B cell ALL with Gilead’s Yescarta following several months later. Although effective in hematological malignancies, CAR response has been limited in solid tumors largely attributed to the heterogeneous and immunosuppressive tumor microenvironment along tumor defense mechanisms, such as antigenic escape. Despite the current challenges of CAR T therapy, this technology is still in its infancy and its promise will continue to grow as scientists continue to develop novel approaches to enhance its efficacy. As its prevalence continues to increase, institutions and pharmaceuticals worldwide are investing in this technology in hopes of driving therapeutic innovation, while providing greater access to their respective populations through clinical trials.Keywords
This publication has 38 references indexed in Scilit:
- Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast CancerCancer Research, 2014
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T CellsClinical Cancer Research, 2013
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T CellsScience Translational Medicine, 2012
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- Adoptive cell therapy for the treatment of patients with metastatic melanomaCurrent Opinion in Immunology, 2009
- Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?Nature Clinical Practice Oncology, 2006
- Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.JCI Insight, 1998
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regionsBiochemical and Biophysical Research Communications, 1987